References
Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S (2014) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii27–iii39
Steins M, Thomas M, Geißler M (2014) Erlotinib. Recent Results Cancer Res 201:109–123
Gridelli C, Maione P, Bareschino MA, Schettino C, Sacco PC, Ambrosio R et al (2010) Erlotinib in the treatment of non-small cell lung cancer: current status and future developments. Anticancer Res 30(4):1301–1310
Tiseo M, Andreoli R, Gelsomino F, Mozzoni P, Azzoni C, Bartolotti M et al (2014) Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer 83(2):265–271
SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359(8):789–799
Zimmerman JL, Shen MC (2013) Rhabdomyolysis. Chest 144(3):1058–1065
Mirrakhimov AE, Mirrakhimov EM (2014) Rhabdomyolysis: some extra clues to diagnosis. Chest 145(2):415–416
Neyra JA, Rocha NA, Bhargava R, Vaidya OU, Hendricks AR, Rodan AR (2015) Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report. BMC Nephrol 16:118. doi:10.1186/s12882-015-0113-6
Moscetti L, Nelli F, Ruggeri EM (2011) Rhabdomyolysis from erlotinib: a case report. Tumori 97(3):415–416
Panel N, Blay JY, Adenis A (2008) Imatinib as a possible cause of severe rhabdomyolysis. N Engl J Med 358:2746–2747
Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH et al (2008) Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther 7(8):2280–2287
Lainey E, Sébert M, Thépot S, Scoazec M, Bouteloup C, Leroy C et al (2012) Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 11(21):4079–4092
Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, Ushijima S et al (2012) Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics 13(5):615–624
Karch FE, Lasagna L (1975) Adverse drug reactions—a critical review. JAMA 234(12):1236–1241
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27(26):4406–4412
Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82(1):33–40
Zwisler ST, Enggaard TP, Noehr-Jensen L, Mikkelsen S, Verstuyft C, Becquemont L, Sindrup SH, Brosen K (2010) The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes. Fundam Clin Pharmacol 24(4):517–524
Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ (2013) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug–drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 88(2):139–148
Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW, Bates SE, Shen T, Ashby CR Jr, Fu LW, Ambudkar SV, Chen ZS (2007) Erlotinib (Tarceva, OSI-774)antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67(22):11012–11020
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koršić, M., Muršić, D., Badovinac, S. et al. Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug–drug interaction. Cancer Chemother Pharmacol 76, 1317–1319 (2015). https://doi.org/10.1007/s00280-015-2885-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2885-6